Supreme Court refuses to hear Saffran v Johnson & Johnson appeal

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Supreme Court refuses to hear Saffran v Johnson & Johnson appeal

The US Supreme Court refused on Monday to hear an appeal from a doctor asking it to reinstate a $482 million patent infringement award against Johnson & Johnson subsidiary Cordis

The court declined to hear Saffran v Johnson & Johnson, in which radiologist Bruce Saffran claimed Cordis infringed a patent he obtained in 1997 in making its Cypher brand of drug-eluting stents, tiny mesh tubes used to prop open weak or narrow arteries.

A district court jury previously found that Cordis violate the patent. But a split Federal Circuit panel did not defer to the district court’s claim construction. The Federal Circuit changed the claim construction and overturned the district court’s finding that Cordis infringed the patent.

Saffran asked the appeals court to put his case on hold and reconsider it alongside Lighting Ballast v Philips, which concerns similar issues about the deference the Federal Circuit should give to a district court’s claim construction. But the Federal Circuit refused.

The Supreme Court’s refusal to accept the case means that Federal Circuit’s decision will stand.

The Supreme Court did not decide whether to accept the WildTangentvUltramercial case on Monday, instead electing to put the question of whether to hear it on hold. If the court chooses to accept that case, it will consider when a patent’s reference to a computer or the Internet is sufficient to make an otherwise unpatentable abstract idea eligible for patent protection.

The court may be waiting to decide whether to accept certiorari of WildTangentvUltramercial until it has resolved Alice v CLS Bank, which concerns similar issues and which the Supreme Court agreed to hear in December. Arguments in that case will take place on March 31 and a decision is expected by the end of June 2014.

more from across site and SHARED ros bottom lb

More from across our site

Submit your nominations to this year's WIBL Americas Awards by January 23
The 2026 Life Sciences EMEA Awards is now open for entries. We are looking forward to reviewing and celebrating the industry's most impressive achievements and landmarks from the past year.
The tie-up between Perkins Coie and Ashurst may generate some striking numbers, but independent IP firms need not worry yet, according to practitioners
Perkins Coie’s US patent prosecution strength could provide Ashurst with an opportunity to enter an untapped market in Australia, but it may not be easy
Mitesh Patel at Reed Smith outlines why the US Copyright Office and courts have so far dismissed AI authorship and how inventors can protect AI-generated works
Xia Zheng, founder of AFD China, discusses balancing legal work with BD, new approaches to complex challenges, and the dangers of ‘over-optimism’
A dispute involving semiconductor technology and a partner's move from Hoffman Eitle to Hoyng Rokh Monegier were also among the top talking points
A former Freshfields counsel and an ex-IBM counsel, who have joined forces at law firm Caldwell, say clients are increasingly sophisticated in their IP demands
Daniel Raymond, who will serve as head of client relations, tells Managing IP that law firms must offer ‘brave’ opinions if they want to keep winning new business
The new outfit, Ashurst Perkins Coie, will bring together around 3,000 lawyers across 23 countries
Gift this article